{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:36:49Z","timestamp":1758040609654,"version":"3.44.0"},"reference-count":58,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":201,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hubei Provincial Health Commission Joint Fund project","award":["WJ2019H461"],"award-info":[{"award-number":["WJ2019H461"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Clinical Practice"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:p><jats:italic>Background<\/jats:italic>. Influence of iguratimod on bone mineral density (BMD) and biomarkers of bone metabolism in patients with rheumatoid arthritis (RA) remains not determined. Accordingly, a meta\u2010analysis was performed for systematical evaluation. <jats:italic>Methods<\/jats:italic>. Relevant randomized controlled trials (RCTs) were retrieved by searching of PubMed, Embase, Cochrane\u2019s Library, China National Knowledge Infrastructure (CNKI), and Wanfang databases. A random\u2010effect model was used to pool the results. <jats:italic>Results<\/jats:italic>. In total, 24 RCTs including 2439 patients with RA contributed to the meta\u2010analysis. Pooled results showed that compared to methotrexate alone, additional use of iguratimod 25\u2009mg Bid for 12\u223c24 weeks significantly improved lumbar\u2010spine BMD (mean difference [MD]: 0.12, 95% confidence interval [CI]: 0.04 to 0.20, <jats:italic>p<\/jats:italic> = 0.002, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200939%) in patients with RA. Moreover, treatment with iguratimod was associated with increased serum osteoprotegerin (MD: 180.36\u2009pg\/ml, 95% CI: 122.52 to 238.20, <jats:italic>p<\/jats:italic> &lt; 0.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200948%), and decreased serum receptor activator for nuclear factor kappa\u2010B ligand (MD: \u221210.65\u2009pmol\/l, 95% CI: \u221215.59 to \u22125.72, <jats:italic>p<\/jats:italic> &lt; 0.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200953%). In addition, iguratimod was associated with increased bone formation markers such as the serum N\u2010terminal middle molecular fragment of osteocalcin (MD: 4.23\u2009ng\/ml, 95% CI: 3.74 to 4.71, <jats:italic>p<\/jats:italic> &lt; 0.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200935%) and total procollagen type I amino\u2010terminal propeptide (MD: 9.10\u2009ng\/ml, 95% CI: 7.39 to 10.80, <jats:italic>p<\/jats:italic> &lt; 0.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200986%), but decreased the bone resorption marker such as serum <jats:italic>\u03b2<\/jats:italic>\u2010C terminal cross\u2010linking telopeptide of type 1 collagen (MD: \u22120.18\u2009pg\/ml, 95% CI: \u22120.21 to \u22120.14, <jats:italic>p<\/jats:italic> &lt; 0.001, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200970%). <jats:italic>Conclusions<\/jats:italic>. Iguratimod could prevent the bone loss and improve the bone metabolism in patients with RA.<\/jats:p>","DOI":"10.1155\/2022\/5684293","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T16:05:08Z","timestamp":1658419508000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Influence of Iguratimod on Bone Metabolism in Patients with Rheumatoid Arthritis: A Meta\u2010analysis"],"prefix":"10.1155","volume":"2022","author":[{"given":"Li","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangling","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenyi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0525-9607","authenticated-orcid":false,"given":"Zhenhua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"key":"e_1_2_8_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2022.102227"},{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108794"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102776"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052871"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2012.153"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000789"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-017-0373-1"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4473-1"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20553"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2175-5"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.601618"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132905"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/484280"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109704"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.780154"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04986-9"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2021","author":"Higgins J.","key":"e_1_2_8_19_2"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_8_22_2","first-page":"391","article-title":"Effects of iguratimod combined with methotrexate on serum M-CSF, IL-6, IL-8 and bone metabolism in patients with rheumatoid arthritis","volume":"2","author":"Tian J. W.","year":"2017","journal-title":"Hainan Medical Journal"},{"key":"e_1_2_8_23_2","first-page":"5500","article-title":"Therapeutic efficacy of iguratimod for old patients with rheumatoid arthritis and its influence on bone metabolism","volume":"11","author":"Cao L. N.","year":"2018","journal-title":"Chinese Journal of Gerontology"},{"key":"e_1_2_8_24_2","first-page":"552","article-title":"Influence of iguratimod combined with methotrexate on serum inflammatory factors and markers of bone metabolism in patients with rheumatoid arthritis","volume":"28","author":"Chen J.","year":"2018","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"key":"e_1_2_8_25_2","first-page":"27","article-title":"Influence of iguratimod combined with methotrexate on serum M-CSF, IL-8, and markers of bone metabolism in patients with rheumatoid arthritis","volume":"29","author":"Du J.","year":"2018","journal-title":"Mol Diagn Treat"},{"key":"e_1_2_8_26_2","first-page":"369","article-title":"Effect of iguratimod in combined with methotrexate on the serum related cytokines and bone metabolism in patients with rheumatoid arthritis","volume":"34","author":"Yan X. Z.","year":"2018","journal-title":"Changchun University of Traditional Chinese Medicine"},{"key":"e_1_2_8_27_2","first-page":"1269","article-title":"Effects of iguratimod for patients with rheumatoid arthritis: influences on biomarkers of bone metabolism","volume":"40","author":"Ding L.","year":"2019","journal-title":"Jilin Medical Journal"},{"key":"e_1_2_8_28_2","first-page":"133","article-title":"Efficacy of iguratimod combined with methotrexatefor for old patients with rheumatoid arthritis and its influence on inflammatory response and bone metabolism","volume":"25","author":"Gao S.","year":"2019","journal-title":"Journal of Contemporary Medicine"},{"key":"e_1_2_8_29_2","first-page":"149","article-title":"Clinical efficacy of guratimod for patients with rheumatoid arthritis and the influence on bone metabolism","volume":"31","author":"Huan W.","year":"2019","journal-title":"Strait Pharmaceutical Journal"},{"key":"e_1_2_8_30_2","first-page":"100","article-title":"Effects of iguratimod combined with methotrexate on inflammatory indexes and bone metabolism in rheumatoid arthritis","volume":"34","author":"Wang Y. E.","year":"2019","journal-title":"Chin Foreign Med Treat"},{"key":"e_1_2_8_31_2","first-page":"1189","article-title":"Iguratimod for the treatment of patients with rheumatoid arthritis and osteoporosis:a clinical study","volume":"32","author":"Xu X. Z.","year":"2019","journal-title":"Mediterranean Journal of Mathematics"},{"key":"e_1_2_8_32_2","first-page":"2415","article-title":"Efficacy of iguratimod combined with methotrexate for rheumatoid arthritis and its effects on inflammatory reaction, bone metabolism and immunity","volume":"38","author":"Zeng Q. H.","year":"2019","journal-title":"Latin American Journal of Pharmacy"},{"key":"e_1_2_8_33_2","first-page":"482","article-title":"Clinical efficacy of iguratimod for rheumatoid arthritis and its impact on bone metabolism","volume":"40","author":"Chen Q. H.","year":"2020","journal-title":"J Gannan Med Univ"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdy220"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/inthealth\/ihaa001"},{"key":"e_1_2_8_36_2","first-page":"60","article-title":"Protective efficacy of iguratimod on bones in patients with rheumatoid arthritis","volume":"33","author":"Li Y.","year":"2020","journal-title":"Med Equipment"},{"key":"e_1_2_8_37_2","first-page":"2886","article-title":"Clinical efficacy of iguratimod in treatment of rheumatoid arthritis and its effect on serological indicators","volume":"26","author":"Lun X. M.","year":"2020","journal-title":"Medieval Review"},{"key":"e_1_2_8_38_2","first-page":"2293","article-title":"The therapeutic effect and mechanism of iguratimod on osteoporosis secondary to rheumatoid arthritis","volume":"41","author":"Yang E. L.","year":"2020","journal-title":"Guangdong Medical Journal"},{"key":"e_1_2_8_39_2","first-page":"110","article-title":"Iguratimod as adjunvant treatment for patients with rheumatoid arthritis and osteoporosis","volume":"14","author":"Fang L. W.","year":"2021","journal-title":"Chinese Journal of Clinical Rational Drug Use"},{"key":"e_1_2_8_40_2","first-page":"3097","article-title":"Analysis of the mechanism of the effect of iguratimod on bone mineral density and serum B-alp and CTX-I in patients with refractory rheumatoid arthritis","volume":"21","author":"Hu G. H.","year":"2021","journal-title":"Progress in Modern Biomedicine"},{"key":"e_1_2_8_41_2","first-page":"73","article-title":"Iguratimod combined with methotrexate for the treatment of patients with rheumatoid arthritis: implications on inflammation and bone metabolism","volume":"16","author":"Jiang X. X.","year":"2021","journal-title":"Internal Medicine"},{"key":"e_1_2_8_42_2","first-page":"1676","article-title":"Effect of combined application of iguratimod in the treatment of active rheumatoid arthritis on bone metabolism, Th17 cells and Treg cells","volume":"13","author":"Li W.","year":"2021","journal-title":"American Journal of Translational Research"},{"key":"e_1_2_8_43_2","first-page":"1383","article-title":"Iguratimod combined with methotrexate on serum M-CSF, IL-6 and bone metabolism in patients with rheumatoid arthritis","volume":"32","author":"Li Y. F.","year":"2021","journal-title":"Mod Diagn Treat"},{"key":"e_1_2_8_44_2","first-page":"482","article-title":"Clinical efficacy of iguratimod for the treatment of patients with rheumatoid arthritis and osteopenia: influences on biomarkers of bone metabolism and peripheral immune parameters","volume":"50","author":"Zhang X. H.","year":"2021","journal-title":"Shaanxi Medical Journal"},{"key":"e_1_2_8_45_2","first-page":"41","article-title":"Clinical efficacy of iguratimod combined with methotrexate in the treatment of rheumatoid arthritis and the influence on patients' bone metabolism","volume":"29","author":"Sun P. C.","year":"2022","journal-title":"Clin Med Engineer"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104354"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2334-5"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddab158"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.14715\/cmb\/2016.62.12.8"},{"key":"e_1_2_8_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3668-8"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7648"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107219"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-021-01206-5"},{"key":"e_1_2_8_54_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-016-1646-z"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.6045"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2016.03.038"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2014-0419"},{"key":"e_1_2_8_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2017.06.005"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijclp\/2022\/5684293.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/ijclp\/2022\/5684293.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2022\/5684293","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:56:58Z","timestamp":1757581018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2022\/5684293"}},"subtitle":[],"editor":[{"given":"Xiao Ming","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1155\/2022\/5684293"],"URL":"https:\/\/doi.org\/10.1155\/2022\/5684293","archive":["Portico"],"relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"type":"print","value":"1368-5031"},{"type":"electronic","value":"1742-1241"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"2022-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5684293"}}